HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

This Phase 2 study is testing whether adding targeted liver radiation therapy to standard systemic drug treatment improves outcomes for patients with advanced intrahepatic cholangiocarcinoma (a type of liver bile duct cancer). **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of intrahepatic cholangiocarcinoma (bile duct cancer within the liver) - You have at least one liver tumor measuring 3 cm or more - Your cancer is either unresectable (cannot be surgically removed) or has spread beyond the liver - You weigh more than 30 kg **You may NOT be eligible if...** - You are currently enrolled in another interventional clinical trial - You have unresolved significant side effects (Grade 2 or higher) from prior cancer treatment - You have active nerve damage (Grade 2 or higher neuropathy) - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.